General description
Cardamonin, a known 2′,4′-dihydroxy-6′-methoxychalcone, was identified as an inhibitor of melanocyte differentiation, among many other pharmacology activities. Cardamonin promoted degradation of intracellular β-catenin while suppressing melanogenesis by down-regulating the expression of MITF and tyrosinase, resulting in decreased melanin content. Furthermore, it was found that cardamonin promoted the degradation of β-catenin through a GSK-3β-independent mechanism, which suggested that Siah-dependent pathway and/or a PKCα-dependent pathway, rather than a GSK-3β-dependent pathway, may mediate intracellularb-catenin degradation by cardamonin.
Cardamonin, a known 2′,4′-dihydroxy-6′-methoxychalcone, was recently identified as an inhibitor of melanocyte differentiation, among many other pharmacology activities. Cardamonin promoted degradation of intracellular β-catenin while suppressing melanogenesis by down-regulating the expression of MITF and tyrosinase, resulting in decreased melanin content. Furthermore, it was found that cardamonin promoted the degradation of β-catenin through a GSK-3β-independent mechanism, which suggested that Siah-dependent pathway and/or a PKCa-dependent pathway, rather than a GSK-3&beta:-dependent pathway, may mediate intracellularb-catenin degradation by cardamonin.